Does Cigna Cover Tirzepatide? Mounjaro, Zepbound & Prior Authorization

Cigna does cover tirzepatide, but the answer splits sharply by what it is prescribed for. Mounjaro, the brand sold for type 2 diabetes, is covered on most Cigna commercial plans with prior authorization. Zepbound, the same molecule sold for weight management and obstructive sleep apnea, is covered only when your employer has chosen to include weight-loss drugs in the plan, and only after you clear a detailed prior authorization. About half of Cigna’s employer clients had opted in as of mid-2025.¹

Mounjaro for Type 2 Diabetes

If you have type 2 diabetes, Mounjaro is covered as medically necessary on most Cigna commercial drug plans, which draw from the Express Scripts National Preferred Formulary.² Prior authorization is required, but once granted it lasts a full year.³

Cigna has an automated approval path that can skip the manual review entirely. If you are at least 10 years old and have filled an oral diabetes medication in the prior 130 days, the Mounjaro claim approves on its own.⁴ If you don’t meet those criteria, your prescriber files a standard prior authorization.

Mounjaro is not covered for weight loss when you don’t have type 2 diabetes. Cigna also considers it experimental for type 1 diabetes, prediabetes, and metabolic syndrome without a type 2 diagnosis.³

Zepbound for Weight Loss

Here is where coverage gets uncertain. Cigna’s own policy acknowledges that “weight loss medications are specifically excluded under many benefit plans,” including both employer group and individual plans.⁵ When Cigna’s general policy and your employer’s plan document conflict, the plan document controls.⁶

The reason comes down to price. GLP-1 drugs carry a list price around $1,060 per month, and employers pay most of that bill.⁷ Many have declined the add-on.

Prior Authorization Criteria

If your plan does cover Zepbound, you still have to clear prior authorization. Under Cigna’s standard national formulary policy (revised April 2026), initial approval runs eight months and requires all of the following:⁶

You are 18 or older.
You have completed at least three months of documented behavioral and dietary modification before starting the drug.
Your baseline BMI is 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, NAFLD, polycystic ovarian syndrome, or coronary artery disease).
You will use the medication alongside a reduced-calorie diet and increased physical activity.

Some employer plans raise the bar. Certain benefit-exclusion-override policies push the BMI threshold to 35, or 27 with at least two comorbidities.⁸ Plans in the Evernorth EncircleRx program require a BMI of at least 32, or 27 with two comorbidities.⁵

“Baseline” means your BMI before you ever started any GLP-1 or GLP-1/GIP medication. If you lost weight on Wegovy and are switching to Zepbound, Cigna evaluates your pre-Wegovy BMI, not your current weight.

One thing Cigna does not require: step therapy within the GLP-1 class. You do not have to fail on liraglutide or semaglutide first. The gate is the three-month lifestyle trial, not a trial of another drug.⁶

Renewing After Eight Months

To continue Zepbound past the initial authorization, you need to have lost at least five percent of your baseline body weight while continuing the lifestyle program. Renewals run one year at a time.⁶

Zepbound for Obstructive Sleep Apnea

Zepbound carries a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, and that opens a second coverage door. In Cigna’s weight-loss policies, OSA counts as a qualifying comorbidity, so a BMI of 27 with documented OSA meets the threshold. The standalone OSA indication also means some plans may authorize the drug under a medical rather than weight-loss benefit, which can bypass a weight-loss exclusion.⁹ Cigna’s policy references the SURMOUNT-OSA trials, which showed tirzepatide significantly reduced the apnea-hypopnea index compared to placebo.⁶

Medicare Coverage

Federal law prohibits Medicare Part D plans from covering medications prescribed solely for weight loss, so Cigna’s Medicare Advantage and Part D plans generally do not pay for Zepbound used for weight management.¹⁰ Mounjaro is available to Medicare beneficiaries with type 2 diabetes through the standard Part D benefit.

Starting July 1, 2026, a time-limited federal program called the Medicare GLP-1 Bridge runs through December 31, 2027, covering Zepbound KwikPen, Wegovy, and Foundayo for weight reduction at a fixed $50 monthly copay. The program routes around individual Part D plans. CMS designated Humana as a central processor to handle prior authorization and claims for all participating beneficiaries nationwide.¹¹

Eligibility is tiered:

BMI 35 or higher, with no additional conditions required.
BMI 30 or higher, with heart failure with preserved ejection fraction, uncontrolled hypertension (despite two medications), or chronic kidney disease stage 3a or above.
BMI 27 or higher, with pre-diabetes, a prior heart attack, prior stroke, or symptomatic peripheral artery disease.

Beneficiaries with type 2 diabetes, moderate-to-severe sleep apnea, or MASH are excluded from the Bridge because those conditions can already be covered through standard Part D channels.¹²

What You Will Pay

When tirzepatide is covered, it typically sits on the highest specialty tier of a four-tier formulary, which generally means the steepest cost-sharing unless some cap applies.⁶ Actual copays vary widely by plan. Some Evernorth clients already offer copays as low as $25 per month, and employers participating in EncircleRx cap member cost at $200 per month for Zepbound.¹

Eli Lilly also runs manufacturer savings programs for commercially insured patients. If your plan covers Zepbound or Mounjaro, the Lilly Savings Card can bring your cost down to as little as $25 for a one- to three-month supply. If your plan does not cover the drug, you can pay $499 per month with the savings card, or $299 to $449 per month through LillyDirect’s self-pay option; the self-pay route requires that you not seek any insurance reimbursement. These programs expire December 31, 2026, and are not available to Medicare, Medicaid, or TRICARE beneficiaries.¹³¹⁴

How to Check Your Own Plan

Because the answer varies so much from one employer to another, the only reliable way to know is to check your specific plan. Log in to the myCigna app or myCigna.com and use the “Price a Medication” tool to see whether Mounjaro or Zepbound is on your formulary and what your estimated cost would be.¹⁵ You can also call the number on the back of your ID card, or pull up your Summary Plan Description or Evidence of Coverage, which will state explicitly whether weight-loss medications are excluded.

What to Do If You Are Denied

A denial does not end the matter. Start by calling Cigna Healthcare customer service at 1-800-882-4462. Sometimes the problem is a missing document or a coding error that gets fixed on the phone.¹⁶

If that doesn’t resolve it, the formal path has three steps:

File a written internal appeal within 180 days of the denial. Include the denial letter, your medical records, and a letter of medical necessity from your prescriber. Cigna completes its review within 60 days.¹⁶
Ask your prescriber to request a peer-to-peer review, a phone conversation between the prescribing doctor and Cigna’s medical director. This often moves faster than a written appeal.
If the internal appeal fails, request an external review by an independent third party. Many states allow this, and the insurer’s denial letter will spell out how it works in your state. External review decisions are generally binding on Cigna.¹⁶

A few practical details separate successful appeals from unsuccessful ones. Make sure your prescriber uses the right diagnosis codes: obesity or OSA codes for Zepbound, a type 2 diabetes code for Mounjaro. Document the three-month lifestyle trial with specific dates, not vague references to past dieting. Include a baseline BMI calculated before any GLP-1 use. Thin lifestyle documentation is one of the most common reasons Cigna denies these requests.

State Mandates That May Change the Default

State legislatures are increasingly requiring insurers to cover anti-obesity medications, which can change what your Cigna plan has to pay for.

North Dakota became the first state to mandate GLP-1 and GIP drug coverage, adding these medications to its ACA Essential Health Benefit benchmark plan effective January 1, 2025. The mandate covers prevention of diabetes and treatment of insulin resistance, metabolic syndrome, or morbid obesity, and applies to non-grandfathered individual and small group plans. Insurers can still use prior authorization and set cost-sharing within federal limits.¹⁷
Colorado’s Diabetes Prevention and Obesity Treatment Act (SB 25-048), effective January 1, 2027, requires large group health plans to cover obesity and prediabetes treatments and requires carriers to offer employers the option to purchase coverage for at least one FDA-approved GLP-1.¹⁸
California’s AB 575, pending as of spring 2025, would require state-regulated plans to cover at least one GLP-1 anti-obesity medication without prior authorization.¹⁹

Connecticut, Iowa, Washington, West Virginia, and Virginia have introduced or advanced similar legislation. Bills in Montana, New Mexico, Texas, and Arkansas failed to advance in the 2025 session, and Mississippi’s governor vetoed a coverage bill that passed its legislature.²⁰ Self-funded employer plans, which many large employers use, are governed by federal ERISA rules and generally sit outside state insurance mandates.

1
CNBC. Cigna Eli Lilly Novo Nordisk Weight Loss Drugs
2
Express Scripts. National Preferred Formulary
3
Cigna. Mounjaro Prior Authorization Coverage Policy
4
Cigna. GLP-1 Agonists Prior Authorization Policy
5
Cigna. Weight Loss GLP-1 Agonists Coverage Policy (IP0621)
6
Cigna. Weight Loss GLP-1 Agonists Prior Authorization Policy
7
Formulary Watch. Express Scripts and Cigna Add Zepbound to Formularies
8
Cigna. Weight Loss GLP-1 Agonists Benefit Exclusion Override Policy (BMI 35)
9
Cigna. Zepbound Drug Quantity Management Policy
10
Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
11
CMS. Medicare GLP-1 Bridge
12
CMS. Medicare GLP-1 Bridge Information for Prescribers
13
Eli Lilly. Zepbound Savings
14
Eli Lilly. Mounjaro Savings and Coverage
15
Cigna. National Preferred 4-Tier Specialty Prescription Drug List
16
Cigna. Appeals and Disputes
17
North Dakota Insurance Department. EHB Changes
18
Colorado General Assembly. SB 25-048
19
CHBRP. AB 575 Obesity Treatment Analysis
20
Pharmacy Times. States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments